From Covance CEO to short-lived LabCorp diagnostics lead, Ratliff lands at AMRI

AMRI Headquarters
AMRI headquarters (AMRI)

John Ratliff’s position has changed three times this fall, but now, much like the falling leaves, he looks to have settled.

The former chief at major CRO Covance (now owned by LabCorp), Ratliff was announced back in October amid a raft of changes that he would be leaving his former post and moving up to lead LabCorp Diagnostics.

But that new role lasted three full business days when, mysteriously, LabCorp announced Ratliff’s immediate departure, with no explanation except one line about taking up a new opportunity.

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

Now, we know what that is: He’s going back to contract research, taking up the chief job at CRO and CDMO Albany Molecular Research (AMRI). He takes over from Michael Mulhern, who moves upstairs to lead the board.

Being it was so short, AMRI makes no mention of Ratliff’s ultra-brief role as diagnostics lead for LabCorp. Unsurprisingly, nor did he: “I am excited to join AMRI and look forward to collaborating with a very talented group of professionals,” said Ratliff in a short statement.

RELATED: Kirchgraber promoted to Covance CEO as former chief takes the reins at LabCorp Diagnostics

“Together we will strengthen AMRI’s position as a market leader and strategic partner for pharmaceutical and biotech companies worldwide. Michael and his team have accomplished a great deal, and I look forward to leading AMRI through its next phase of growth.”

Suggested Articles

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.

The site brings together all the units involved in the identification and support of promising drug development projects.

In a mix-up of trial-based solutions, CRO Parexel is using its recent partnership with Datavant to run a pact with life science data firm TriNetX.